loadpatents
name:-0.0084071159362793
name:-0.0071687698364258
name:-0.0035450458526611
Pando; Matthew P. Patent Filings

Pando; Matthew P.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pando; Matthew P..The latest application filed is for "substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde 10a)".

Company Profile
0.6.5
  • Pando; Matthew P. - Paris FR
  • Pando; Matthew P. - Arlington VA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Grant 9,902,710 - Leblond , et al. February 27, 2
2018-02-27
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Grant 9,670,181 - Leblond , et al. June 6, 2
2017-06-06
Substituted 6, 7-dialkoxy-3-isoquinoline Derivatives As Inhibitors Of Phosphodiesterase 10 (pde 10a)
App 20160264549 - Leblond; Bertrand ;   et al.
2016-09-15
Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Grant 9,200,016 - Leblond , et al. December 1, 2
2015-12-01
Substituted 6, 7-dialkoxy-3-isoquinoline Derivatives As Inhibitors Of Phosphodiesterase 10 (pde 10a)
App 20150158895 - Leblond; Bertrand ;   et al.
2015-06-11
Substituted 6,7-dialkoxy-3-isoquinolinol Derivatives As Inhibitors Of Phosphodiesterase 10 (pde 10a)
App 20140309253 - Leblond; Bertrand ;   et al.
2014-10-16
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
Grant 8,772,316 - Leblond , et al. July 8, 2
2014-07-08
Methods For Treating Diseases Of The Retina
App 20120214842 - Donello; John E. ;   et al.
2012-08-23
Substituted 6,7-dialkoxy-3-isoquinolinol Derivatives As Inhibitors Of Phosphodiesterase 10 (pde10a)
App 20120214837 - Leblond; Bertrand ;   et al.
2012-08-23
Prostate specific genes and the use thereof as targets for prostate cancer therapy
Grant 7,834,163 - Einstein , et al. November 16, 2
2010-11-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed